{
  "@context": "aku-v2",
  "@type": "pharmacology",
  "@id": "vascular:pharmacology:antiplatelet:clopidogrel",
  "metadata": {
    "version": "1.0.0",
    "created": "2026-01-07T00:55:00.000Z",
    "updated": "2026-01-07T00:55:00.000Z",
    "contributors": ["vascular-surgery-agent"],
    "confidence": 0.95,
    "status": "validated"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pharmacology",
    "type": "pharmacology",
    "difficulty": "intermediate",
    "importance": "high"
  },
  "content": {
    "identifier": "PHARM-011",
    "title": "Clopidogrel (P2Y12 Inhibitor)",
    "definition": "Thienopyridine prodrug antiplatelet agent that irreversibly inhibits P2Y12 ADP receptor on platelets.",
    "concepts": [
      {
        "concept_id": "mechanism",
        "term": "Mechanism of Action",
        "definition": "Prodrug requiring hepatic CYP2C19 activation to active metabolite that irreversibly binds P2Y12 receptor.",
        "clinical_features": {
          "receptor": "P2Y12 ADP receptor",
          "binding": "Irreversible (platelet lifespan effect)",
          "cyp_activation": "CYP2C19 primary, also CYP3A4, CYP1A2",
          "onset": "2-4 hours with loading dose"
        }
      },
      {
        "concept_id": "dosing",
        "term": "Clopidogrel Dosing",
        "definition": "Loading and maintenance dosing for various vascular indications.",
        "clinical_features": {
          "loading": "300-600 mg",
          "maintenance": "75 mg daily",
          "acs": "600 mg load, 75 mg daily for 12 months",
          "stroke": "75 mg daily (no loading per CHANCE)"
        }
      },
      {
        "concept_id": "resistance",
        "term": "Clopidogrel Resistance",
        "definition": "Variable antiplatelet response due to genetic and drug factors.",
        "clinical_features": {
          "cyp2c19_polymorphism": {
            "poor_metabolizers": "2-15% of population",
            "lof_alleles": "*2, *3 most common",
            "clinical_impact": "Increased stent thrombosis risk"
          },
          "drug_interactions": ["PPI (omeprazole strongest)", "CYP2C19 inhibitors"],
          "alternatives": ["Prasugrel", "Ticagrelor"]
        }
      },
      {
        "concept_id": "indications",
        "term": "Vascular Surgery Indications",
        "definition": "Role of clopidogrel in vascular surgery patients.",
        "clinical_features": {
          "carotid_stent": "DAPT for minimum 30 days, ideally 3-6 months",
          "peripheral_stent": "DAPT for 1-3 months",
          "aspirin_intolerance": "Alternative monotherapy",
          "pad": "May be superior to aspirin (CAPRIE)"
        }
      }
    ],
    "clinical_features": {
      "perioperative": "Hold 5-7 days pre-elective surgery",
      "testing": "CYP2C19 genotyping or platelet function testing in high-risk"
    },
    "diagnostic_criteria": {
      "platelet_inhibition": "PRU <208 considered adequate on VerifyNow"
    }
  },
  "relationships": [
    {"type": "combined_with", "target": "vascular:pharmacology:aspirin"},
    {"type": "alternative_to", "target": "vascular:pharmacology:ticagrelor"},
    {"type": "used_in", "target": "vascular:procedures:stenting"}
  ],
  "provenance": {
    "sources": [
      {"reference": "Mega JL et al. N Engl J Med. 2009;360:354-362", "type": "primary"},
      {"reference": "Wallentin L et al. Lancet. 2010;376:1320-1328", "type": "primary"}
    ],
    "extraction_method": "expert-review"
  }
}
